Stockscreener 앱 받기
9.3083
2.65%
-0.3017
전일 마감가:
$9.61
열려 있는:
$9.51
하루 거래량:
666.85K
Relative Volume:
0.28
시가총액:
$953.34M
수익:
$187.64M
순이익/손실:
$-95.00M
주가수익비율:
-9.7982
EPS:
-0.95
순현금흐름:
$-69.02M
1주 성능:
+0.38%
1개월 성능:
+8.28%
6개월 성능:
+41.53%
1년 성능:
-23.32%
1일 변동 폭
$9.15
$9.7112
1주일 범위
$8.35
$9.7112
52주 변동 폭
$5.635
$13.53
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
명칭
Day One Biopharmaceuticals Inc
전화
650 484-0899
주소
1800 SIERRA POINT PARKWAY, SUITE 200, BRISBANE
DAWN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DAWN
Day One Biopharmaceuticals Inc
|
9.285 | 986.71M | 187.64M | -95.00M | -69.02M | -0.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.80 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
808.08 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
797.02 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
169.35 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2024-10-09 | 재확인 | Needham | Buy |
| 2024-08-01 | 업그레이드 | BofA Securities | Underperform → Buy |
| 2024-04-24 | 재확인 | Needham | Buy |
| 2023-04-25 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2023-02-08 | 개시 | CapitalOne | Overweight |
| 2023-02-03 | 개시 | Oppenheimer | Perform |
| 2022-12-15 | 개시 | H.C. Wainwright | Buy |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-12-05 | 개시 | Goldman | Buy |
| 2022-12-01 | 개시 | BofA Securities | Buy |
모두보기
Day One Biopharmaceuticals Inc 주식(DAWN)의 최신 뉴스
Day One Biopharmaceuticals completes acquisition of Mersana Therapeutics - Investing.com
Day One Biopharmaceuticals Completes Acquisition of Mersana Therapeutics - TipRanks
Day One Biopharmaceuticals Signs Contingent Value Rights Agreement With Computershare - TradingView — Track All Markets
Day One Biopharmaceuticals Completes Acquisition of Mersana Therapeutics to Enhance Oncology Pipeline - Quiver Quantitative
Day One Completes Acquisition of Mersana Therapeutics - GlobeNewswire
Day One Biopharmaceuticals (NASDAQ:DAWN) Nasdaq Index Biomarker Science - Kalkine Media
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
(DAWN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
When Can We Expect A Profit From Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)? - 富途牛牛
How The Mersana Deal Is Rewriting The Story Behind Day One Biopharmaceuticals Valuation - Yahoo Finance
Is Day One Biopharmaceuticals Inc. stock dividend yield sustainableJuly 2025 Trends & Growth Focused Stock Pick Reports - Улправда
Price-Driven Insight from (DAWN) for Rule-Based Strategy - Stock Traders Daily
Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Down 6%What's Next? - MarketBeat
Will Day One Biopharmaceuticals Inc. stock benefit from automationWeekly Investment Summary & Smart Allocation Stock Tips - DonanımHaber
We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Easily Afford To Drive Business Growth - Sahm
Day One Pharmaceuticals: Stock Surges Ahead Of Promising 2026I'm Bullish (NASDAQ:DAWN) - Seeking Alpha
Day One Biopharmaceuticals (NASDAQ:DAWN) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Day One Biopharmaceuticals Reports Promising FIREFLY-1 Trial Results - timothysykes.com
FuelCell Energy Posts Strong Q4 Results, Joins Trump Media & Technology, Micron Technology, Lululemon And Other Big Stocks Moving Higher On Thursday - Sahm
Day One Biopharmaceuticals (NASDAQ:DAWN) Gains Visibility Nasdaq Today - Kalkine Media
Day One Biopharmaceuticals (NASDAQ:DAWN) Trading Up 5.5%Still a Buy? - MarketBeat
Day One Biopharmaceuticals Target of Unusually Large Options Trading (NASDAQ:DAWN) - MarketBeat
Day One Biopharma (DAWN) announces positive 3-year follow-up results from pivotal phase 2 FIREFLY-1 trial of OJEMDA (tovorafenib) - MSN
Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Hudson Bay Capital Management LP Has $8.43 Million Holdings in Day One Biopharmaceuticals, Inc. $DAWN - MarketBeat
Day One Biopharma (DAWN) Announces Positive 3-Year Follow-up Results from Pivotal Phase 2 FIREFLY-1 Trial of OJEMDA (Tovorafenib) - Finviz
20 Stocks That Will Double in 2026 - Insider Monkey
Halper Sadeh LLC Encourages FFWM, MRSN, FSUN Shareholders to Contact the Firm to Discuss Their Rights - FinancialContent
Braidwell LP Has $14.18 Million Position in Day One Biopharmaceuticals, Inc. $DAWN - MarketBeat
Day One Biopharmaceuticals Reports Strong Q3 2025 Results - MSN
Day One Biopharmaceuticals Inc. (DAWN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Day One Biopharmaceuticals Reports Strong Q3 2025 Growth - MSN
Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Down 4.9%What's Next? - MarketBeat
Why The Narrative Around Day One Biopharmaceuticals Is Shifting After The Mersana Acquisition - Yahoo Finance
Day One Biopharmaceuticals Expands with Mersana Acquisition - StocksToTrade
Day One Biopharmaceuticals (NASDAQ:DAWN) Sees Large Volume IncreaseTime to Buy? - MarketBeat
(DAWN) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Day One’s FIREFLY Trial Shows Promise in Pediatric Cancer Treatment - timothysykes.com
Day One Biopharmaceuticals (NASDAQ:DAWN) Nasdaq Futures Clinical-Stage Innovation - Kalkine Media
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
180,133 Shares in Day One Biopharmaceuticals, Inc. $DAWN Bought by Schroder Investment Management Group - MarketBeat
MRSN Stock Soars Over 200% Pre-Market After Day One Acquisition Deal - MSN
How buybacks impact Day One Biopharmaceuticals Inc. stock valueTrade Performance Summary & Verified High Yield Trade Plans - Newser
Day One to buy Mersana Therapeutics for $25/share upfront - MSN
Day One Biopharmaceuticals, Inc. $DAWN Shares Purchased by Geode Capital Management LLC - MarketBeat
Updated FIREFLY-1 Data Further Support Tovorafenib as a SOC in R/R Pediatric Low-Grade Glioma - OncLive
Will Day One Biopharmaceuticals Inc. stock deliver shareholder valueJuly 2025 Patterns & Fast Exit and Entry Strategy Plans - Newser
Day One Biopharmaceuticals, Inc. $DAWN Shares Purchased by Virtus Investment Advisers LLC - MarketBeat
Franklin Resources Inc. Purchases 79,255 Shares of Day One Biopharmaceuticals, Inc. $DAWN - MarketBeat
What drives Day One Biopharmaceuticals Inc stock pricePrice Momentum Alerts & Investor Community Interactions - earlytimes.in
(DAWN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Day One Biopharmaceuticals Inc (DAWN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.77%
자본화:
|
볼륨(24시간):